On the public citation graph

Phase 1 study of napabucasin, a cancer stemness inhibitor, in patients with advanced solid tumors

https://doi.org/10.1007/s00280-020-04059-3
0 signed · 74 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/cam4.675openalex-snapshot
Suppression of prostate cancer progression by cancer cell stemness inhibitor napabucasin
inferredcites →https://doi.org/10.1002/sctm.17-0138openalex-snapshot
Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development
inferredcites →https://doi.org/10.1016/j.bbcan.2013.12.005openalex-snapshot
Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors
inferredcites →https://doi.org/10.1016/j.ejca.2008.10.026openalex-snapshot
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
inferredcites →https://doi.org/10.1016/s2468-1253(18)30009-8openalex-snapshot
Napabucasin versus placebo in refractory advanced colorectal cancer: a randomised phase 3 trial
inferredcites →https://doi.org/10.1038/nm0797-730openalex-snapshot
Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell
inferredcites →https://doi.org/10.1038/onc.2014.72openalex-snapshot
Drug-repositioning screening identified piperlongumine as a direct STAT3 inhibitor with potent activity against breast cancer
inferredcites →https://doi.org/10.1038/srep17663openalex-snapshot
Multiple regulation pathways and pivotal biological functions of STAT3 in cancer
inferredcites →https://doi.org/10.1073/pnas.1424171112openalex-snapshot
Suppression of cancer relapse and metastasis by inhibiting cancer stemness
inferredcites →https://doi.org/10.1146/annurev.cellbio.22.010305.104154openalex-snapshot
The Biology of Cancer Stem Cells
inferredcites →https://doi.org/10.1158/1078-0432.ccr-19-0302openalex-snapshot
Bioactivation of Napabucasin Triggers Reactive Oxygen Species–Mediated Cancer Cell Death
inferredcites →https://doi.org/10.1158/1078-0432.ccr-20-1803openalex-snapshot
Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial)
inferredcites →https://doi.org/10.1200/jco.2013.31.15_suppl.2542openalex-snapshot
A dose-escalation phase I study of a first-in-class cancer stemness inhibitor in patients with advanced malignancies.
inferredcites →https://doi.org/10.1200/jco.2014.32.15_suppl.2546openalex-snapshot
A phase I extension study of BBI608, a first-in-class cancer stem cell (CSC) inhibitor, in patients with advanced solid tumors.
inferredcites →https://doi.org/10.1200/jco.2015.33.15_suppl.4069openalex-snapshot
Phase Ib/II study of cancer stem cell (CSC) inhibitor BBI608 combined with paclitaxel in advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.1084openalex-snapshot
A phase 2 study of napabucasin with weekly paclitaxel in previously treated metastatic breast cancer.
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.tps3619openalex-snapshot
CanStem303C trial: A phase III study of napabucasin (BBI-608) in combination with 5-fluorouracil (5-FU), leucovorin, irinotecan (FOLFIRI) in adult patients with previously treated metastatic colorectal cancer (mCRC).
inferredcites →https://doi.org/10.1200/jco.2017.35.15_suppl.tps4148openalex-snapshot
CanStem111P trial: A phase III study of napabucasin (BBI-608) plus nab-paclitaxel (nab-PTX) with gemcitabine (gem) in adult patients with metastatic pancreatic adenocarcinoma (mPDAC).
inferredcites →https://doi.org/10.1200/jco.2017.35.4_suppl.593openalex-snapshot
Cancer stemness inhibition and chemosensitization: Phase 1b/II study of cancer stemness inhibitor napabucasin (BBI-608) with FOLFIRI +/- bevacizumab (Bev) administered to colorectal cancer (CRC) patients (pts).
inferredcites →https://doi.org/10.1200/jco.2017.35.4_suppl.677openalex-snapshot
BBI608-224: A phase Ib/II study of cancer stemness inhibitor napabucasin (BBI-608) administered with panitumumab in KRAS wild-type patients with metastatic colorectal cancer.
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.3530openalex-snapshot
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.4010openalex-snapshot
The BRIGHTER trial: A phase 3 randomized double-blind study of napabucasin (NAPA) plus paclitaxel (PTX) versus placebo (PBO) plus PTX in patients (pts) with pretreated advanced gastric and gastroesophageal junction (GEJ) adenocarcinoma.
inferredcites →https://doi.org/10.1200/jco.2018.36.15_suppl.4110openalex-snapshot
Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).
inferredcites →https://doi.org/10.1200/jco.2018.36.4_suppl.760openalex-snapshot
Multicenter phase I/II trial of BBI608 and pembrolizumab combination in patients with metastatic colorectal cancer (SCOOP Study): EPOC1503.
inferredcites →https://doi.org/10.3324/haematol.2010.027086openalex-snapshot
-catenin is constitutively active and increases STAT3 expression/activation in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4179186openalex-extracted
inferred← citeshttps://doi.org/10.1002/biof.70045openalex-snapshot
The Role of STAT3 in Cancer: From Metabolic Regulation to Therapeutic Targeting
inferred← citeshttps://doi.org/10.1002/cpdd.961openalex-snapshot
Napabucasin Drug‐Drug Interaction Potential, Safety, Tolerability, and Pharmacokinetics Following Oral Dosing in Healthy Adult Volunteers
inferred← citeshttps://doi.org/10.1002/ijc.33544openalex-snapshot
Nanog is a promising chemoresistant stemness marker and therapeutic target by iron chelators for esophageal cancer
inferred← citeshttps://doi.org/10.1002/ijc.70421openalex-snapshot
Reprogramming innate immunity to overcome endocrine resistance in estrogen receptor‐positive breast cancer
inferred← citeshttps://doi.org/10.1002/inmd.70089openalex-snapshot
Napabucasin transforms liver microenvironment and boosts immunotherapy efficacy by converting potential metastases into “hot” tumors
inferred← citeshttps://doi.org/10.1002/prp2.874openalex-snapshot
Effects of a reactive oxygen species generator, napabucasin (BBI608), on tolerability, safety, pharmacokinetics, and QT/QTc interval in healthy volunteers
inferred← citeshttps://doi.org/10.1007/s10147-021-01987-9openalex-snapshot
Phase I study of napabucasin in combination with FOLFIRI + bevacizumab in Japanese patients with metastatic colorectal cancer
inferred← citeshttps://doi.org/10.1007/s11523-023-00983-5openalex-snapshot
Molecularly Stratified Treatment Options in Primary Refractory DLBCL/HGBL with MYC and BCL2 or BCL6 Rearrangements (HGBL, NOS with MYC/BCL6)
inferred← citeshttps://doi.org/10.1007/s12015-026-11057-0openalex-snapshot
From Signaling Pathways to Combination Therapy: Bioactive Compounds against Cancer Stem Cells
inferred← citeshttps://doi.org/10.1007/s12672-025-04129-zopenalex-snapshot
Identification of ITGA2 as a methylation-regulated oncogene through a CeRNA network in papillary thyroid carcinoma
inferred← citeshttps://doi.org/10.1007/s40268-023-00416-8openalex-snapshot
A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetics of Napabucasin Combined with Sorafenib in Japanese Patients with Unresectable Hepatocellular Carcinoma
inferred← citeshttps://doi.org/10.1016/b978-0-443-21790-6.00006-7openalex-snapshot
Mechanisms of resistance of antibody-drug conjugates—Obstacles to overcome
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2024.122766openalex-snapshot
Napabucasin deactivates STAT3 and promotes mitoxantrone-mediated cGAS-STING activation for hepatocellular carcinoma chemo-immunotherapy
inferred← citeshttps://doi.org/10.1016/j.bioorg.2023.107095openalex-snapshot
Targeting JAK2/STAT3 for the treatment of cancer: A review on recent advancements in molecular development using structural analysis and SAR investigations
inferred← citeshttps://doi.org/10.1016/j.bmcl.2022.128992openalex-snapshot
Comparative Analysis of p-Terphenylquinone and Seriniquinone Derivatives as Reactive Oxygen Species-Modulating Agents
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.103920openalex-snapshot
Cancer stem cells in colorectal cancer: Signaling pathways involved in stemness and therapy resistance
inferred← citeshttps://doi.org/10.1016/j.ejmcr.2026.100326openalex-snapshot
1,4 -naphthoquinone derivatives with anticancer potential: A comprehensive review
inferred← citeshttps://doi.org/10.1016/j.ejmech.2024.116249openalex-snapshot
Unlocking the potential of 1,4-naphthoquinones: A comprehensive review of their anticancer properties
inferred← citeshttps://doi.org/10.1016/j.ejmech.2026.118774openalex-snapshot
Discovery of novel napabucasins bearing sulfonylpiperazine scaffolds as potent STAT3 inhibitors for the treatment of prostate cancer
inferred← citeshttps://doi.org/10.1016/j.ejphar.2025.178079openalex-snapshot
Targeting STAT3 pathway: A promising immunotherapeutic strategy for triple-negative breast cancer – Current status and future outlooks
inferred← citeshttps://doi.org/10.1016/j.gendis.2026.102096openalex-snapshot
Targeting JAK/STAT axis in solid tumors: resolving the therapeutic paradox through upstream suppression and downstream disruption
inferred← citeshttps://doi.org/10.1016/j.neo.2021.10.003openalex-snapshot
STAT3 as a mediator of oncogenic cellular metabolism: Pathogenic and therapeutic implications
inferred← citeshttps://doi.org/10.1016/j.tim.2026.08.013openalex-snapshot
Molecular pathways linking the gut microbiome to antitumor immunity
inferred← citeshttps://doi.org/10.1016/j.tips.2026.07.004openalex-snapshot
STAT3 signaling inhibitors for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.trecan.2026.08.006openalex-snapshot
Macrophage-directed therapeutic strategies in cancer
inferred← citeshttps://doi.org/10.1021/acs.jmedchem.0c01336openalex-snapshot
Cancer Stem Cell (CSC) Inhibitors in Oncology—A Promise for a Better Therapeutic Outcome: State of the Art and Future Perspectives
inferred← citeshttps://doi.org/10.1021/acs.oprd.3c00001openalex-snapshot
First-Generation Process Development of Napabucasin and Impurity Control Strategy
inferred← citeshttps://doi.org/10.1038/s41392-026-02887-yopenalex-snapshot
Translational insights and clinical challenges of targeting cancer stem cells
inferred← citeshttps://doi.org/10.1038/s41417-022-00548-0openalex-snapshot
Proteomic time course of breast cancer cells highlights enhanced sensitivity to Stat3 and Src inhibitors prior to endocrine resistance development
inferred← citeshttps://doi.org/10.1038/s41467-025-62477-4openalex-snapshot
2-oxoglutarate:acceptor oxidoreductase-catalyzed redox cycling effectively targets coccoid forms of Helicobacter pylori
inferred← citeshttps://doi.org/10.1080/13543784.2021.1891222openalex-snapshot
An update on investigational therapies that target STAT3 for the treatment of cancer
inferred← citeshttps://doi.org/10.1111/imcb.70078openalex-snapshot
Targeting JAK–STAT signaling for autoimmune diseases: current understanding, clinical advances, and emerging directions
inferred← citeshttps://doi.org/10.1111/jgh.15937openalex-snapshot
The emerging era of personalized medicine in advanced colorectal cancer
inferred← citeshttps://doi.org/10.1172/jci.insight.136176openalex-snapshot
Potent antitumor effects of cell-penetrating peptides targeting STAT3 axis
inferred← citeshttps://doi.org/10.1172/jci157917openalex-snapshot
IL-20RB mediates tumoral response to osteoclastic niches and promotes bone metastasis of lung cancer
inferred← citeshttps://doi.org/10.1186/s12890-023-02354-2openalex-snapshot
Genomic features and its potential implication in bone oligometastatic NSCLC
inferred← citeshttps://doi.org/10.1186/s13046-024-02949-5openalex-snapshot
Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery
inferred← citeshttps://doi.org/10.2174/1574892818666230803100554openalex-snapshot
Natural STAT3 Inhibitors for Cancer Treatment: A Comprehensive Literature Review
inferred← citeshttps://doi.org/10.3389/fonc.2023.1129405openalex-snapshot
Primary refractory plasmablastic lymphoma: A precision oncology approach
inferred← citeshttps://doi.org/10.3389/fonc.2024.1429194openalex-snapshot
Worldwide research trends on bone metastases of lung cancer: a bibliometric analysis
inferred← citeshttps://doi.org/10.3390/cancers14051330openalex-snapshot
Ipilimumab, Pembrolizumab, or Nivolumab in Combination with BBI608 in Patients with Advanced Cancers Treated at MD Anderson Cancer Center
inferred← citeshttps://doi.org/10.3390/ijms27020785openalex-snapshot
Bone Metastasis in Estrogen Receptor-Positive Breast Cancer: Molecular Insights and Therapeutic Advances
inferred← citeshttps://doi.org/10.3390/molecules28155678openalex-snapshot
The Anticancer Effect of Napabucasin (BBI608), a Natural Naphthoquinone
inferred← citeshttps://doi.org/10.3892/br.2024.1863openalex-snapshot
STAT3 and the STAT3‑regulated inhibitor of apoptosis protein survivin as potential therapeutic targets in colorectal cancer (Review)
inferred← citeshttps://doi.org/10.53846/goediss-8679openalex-snapshot
HSP90-stabilized proteins as therapeutic targets in cancer
inferred← citeshttps://doi.org/10.53846/goediss-8719openalex-snapshot
Targeting JAK/STAT signalling for sensitization of colorectal cancer cells to chemoradiotherapy
inferred← citeshttps://doi.org/10.6084/m9.figshare.22609952openalex-snapshot
Additional file 1 of Genomic features and its potential implication in bone oligometastatic NSCLC
inferred← citeshttps://doi.org/10.6084/m9.figshare.22609955openalex-snapshot
Additional file 2 of Genomic features and its potential implication in bone oligometastatic NSCLC
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.